Showing results (41-50 of 64) with videos related to
Sort By:
Pageof 7
Chemical Science|January 13, 2022
Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small moleculesFrancesco Gentile, Michael Fernandez, Fuqiang Ban, et al.Frontiers in Oncology|February 18, 2021
Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer TherapeuticsVictor M Matias-Barrios, Mariia Radaeva, Yi Song, et al.Biorxiv : the Preprint Server for Biology|September 18, 2025
Structure-based discovery of inhibitors of Mac1 domain of nonstructural protein-3 of SARS-CoV-2 by machine learning-augmented screening of chemical spaceFuqiang Ban, Rahul Ravichandran, Galen J Correy, et al.Molecular Cancer Therapeutics|March 10, 2025
5'-S-(3-aminophenyl)-5'-thioadenosine, a novel chemoprotective agent for reducing toxic side effects of fluorouracil in treatment of MTAP-deficient cancersSi Zhang, Hui Xue, Nelson K Y Wong, et al.Journal of Chemical Information and Modeling|March 17, 2023
Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent InhibitorsOlivia Garland, Anh-Tien Ton, Shoeib Moradi, et al.Journal of Medicinal Chemistry|January 11, 2013
Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivativesRavi Shashi Nayana Munuganti, Eric Leblanc, Peter Axerio-Cilies, et al.Cancer Letters|August 31, 2018
Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancerKush Dalal, Fuqiang Ban, Huifang Li, et al.Cancers|July 24, 2021
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate CancerFuqiang Ban, Eric Leblanc, Ayse Derya Cavga, et al.Chemistry & Biology|December 3, 2014
Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancerRavi S N Munuganti, Mohamed D H Hassona, Eric Leblanc, et al.Molecular Cancer Therapeutics|August 5, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin InteractionsKush Dalal, Meixia Che, Nanette S Que, et al.Pageof 7